SBV Journal of Basic, Clinical and Applied Health Science

Register      Login

VOLUME 4 , ISSUE 4 ( October-December, 2021 ) > List of Articles

SHORT COMMUNICATION

COVID-19 and Mucormycosis: Predisposing Factors and Preventive Strategies

Prateek S Shrivastava, Saurabh R Shrivastava

Keywords : COVID-19, Diabetes mellitus, Mucormycosis, Opportunistic infection

Citation Information : Shrivastava PS, Shrivastava SR. COVID-19 and Mucormycosis: Predisposing Factors and Preventive Strategies. 2021; 4 (4):92-94.

DOI: 10.5005/jp-journals-10082-03126

License: CC BY-NC 4.0

Published Online: 24-12-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2. COVID-19 has been associated with a wide range of opportunistic infections, viz. bacterial and fungal. Mucormycosis is one of the most deadly and life-threatening invasive fungal infections which has typically seen a rising trend with the rise in COVID-19 cases. Patients who are at higher risk to develop mucormycosis include those with uncontrolled diabetes mellitus, steroid-induced immunosuppression, acquired immunodeficiency syndrome, immunosuppression due to malignancies or posttransplant, prolonged stay in intensive care units, patients on oxygen therapy and/or mechanical ventilation, etc. Preventive strategies for mucormycosis should aim at addressing the underlying risk factors in COVID-19 patients, airborne infection control at the facility level, as well as personal protective measures at the individual level. Finally, a high index of suspicion, clinically, on the part of the treating physician can go a long way in prompt diagnosis and initiation of aggressive antifungal therapy and extensive surgical management of mucormycosis, leading to an improved outcome.


PDF Share
  1. WHO Coronovirus (COVID-19) Dashboard Overview. World Health Organization; 2021. Available from: https://covid19.who.int/ [Last Accessed on August 13, 2021].
  2. Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al. Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections. Open Forum Infect Dis 2021;8(6):ofab201. DOI: 10.1093/ofid/ofab201.
  3. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020;31:1–8. DOI: 10.1007/s11046-020-00462-9.
  4. Fekkar A, Lampros A, Mayaux J, Poignon C, Demeret S, Constantin JM, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med 2021;203(3):307–317. DOI: 10.1164/rccm.202009-3400OC.
  5. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;5:1–10. DOI: 10.1007/s11046-021-00528-2.
  6. Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses 2007;50(4):290–296. DOI: 10.1111/j.1439-0507.2007.01364.x.
  7. Scheckenbach K, Cornely O, Hoffmann TK, Engers R, Bier H, Chaker A, et al. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx 2010;37(3):322–328. DOI: 10.1016/j.anl.2009.09.001.
  8. Munir N, Jones NS. Rhinocerebral mucormycosis with orbital and intracranial extension: a case report and review of optimum management. J Laryngol Otol 2007;121(2):192–195. DOI: 10.1017/S0022215106003409.
  9. Vairaktaris E, Moschos MM, Vassiliou S, Baltatzis S, Kalimeras E, Avgoustidis D, et al. Orbital cellulitis, orbital subperiosteal and intraorbital abscess. Report of three cases and review of the literature. J Craniomaxillofac Surg 2009;37(3):132–136. DOI: 10.1016/j.jcms.2008.10.007.
  10. Gillespie MB, O'Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am 2000;33(2):323–334. DOI: 10.1016/s0030-6665(00)80008-0.
  11. Ballester DG, González-García R, García CM, Ruiz-Laza L, Gil FM. Mucormycosis of the head and neck: report of five cases with different presentations. J Craniomaxillofac Surg 2012;40(7):584–591. DOI: 10.1016/j.jcms.2011.10.015.
  12. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5):634–653. DOI: 10.1086/432579.
  13. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020;14(4):303–310. DOI: 10.1016/j.dsx.2020.04.004.
  14. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 2021;7(4):298. DOI: 10.3390/jof7040298.
  15. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193–199. DOI: 10.1007/s00592-009-0109-4.
  16. Kothandaraman N, Rengaraj A, Xue B, Yew WS, Velan SS, Karnani N, et al. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab 2021;320(1):E139–E150. DOI: 10.1152/ajpendo.00480.2020.
  17. Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19 a meta-analysis. JAMA 2020;324(13):1330–1341. DOI: 10.1001/jama.2020.17023.
  18. Koushiappi E, Porfyridis I, Karagiannis C, Adamide T, Georgiou A. Pulmonary mucormycosis (zygomycosis) presenting as an infective exacerbation of chronic obstructive pulmonary disease. Eur J Case Rep Intern Med 2018;5(12). DOI: 10.12890/2018_000995.
  19. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021;135(5):442–447. DOI: 10.1017/S0022215121000992.
  20. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19? Cureus 2020;12(9):e10726. DOI: 10.7759/cureus.10726.
  21. Ibrahim A, Spellberg B, Edwards Jr J. Iron acquisition: a novel prospective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008;21(6):620. DOI: 10.1097/QCO.0b013e 3283165fd1.
  22. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71(9):2459–2468. DOI: 10.1093/cid/ciaa530.
  23. Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect 2020;9(1):1958–1964. DOI: 10.1080/22221751.2020.1812437.
  24. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):475–481. DOI: 10.1016/S2213-2600(20)30079-5.
  25. Banerjee M, Pal R, Bhadada SK. Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad Med J 2021. DOI: 10.1136/postgradmedj-2021-140537.
  26. Mucormycosis in COVID-19. AIIMS COVID portal. New Delhi: AIIMS; 2021. Available from: https://covid.aiims.edu/mucormycosis-in-covid-19/ [Last Accessed on July 6, 2021].
  27. Elinav H, Zimhony O, Cohen MJ, Marcovich AL, Benenson S. Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect 2009;15(7):693–697. DOI: 10.1111/j.1469-0691.2009.02884.x.
  28. Goldstein EJ, Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009;48(12):1743–1751. DOI: 10.1086/599105.
  29. Mucormycosis key facts. India: World Health Organization; 2021. Available from: https://www.who.int/india/emergencies/coronavirus-disease-(covid-19)/mucormycosis [Last Accessed on July 6, 2021].
  30. Mucormycosis–people at risk and prevention. Center for Disease Control and Prevention; 2021. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/risk-prevention.html [Last Accessed on July 7, 2021].
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.